Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 14Recruiting 4Terminated 3Unknown 2Suspended 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1NET 1Gynecologic 1Genitourinary 1Gastrointestinal 1Endocrine 1Breast 1

Conditions

Sarcoma 7Osteosarcoma 4Lymphoma 3Prostatic Neoplasms 2Neoplasm Metastasis 2Melanoma 2Gliosarcoma 2Glioblastoma 2Gastrointestinal Stromal Tumors 2Dendritic Cell Sarcoma, Interdigitating 2Colorectal Neoplasms 2Carcinoma, Renal Cell 2Breast Neoplasms 2Vulvar Neoplasms 1Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Sarcoma, Ewing 1Rhabdomyosarcoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neuroendocrine Tumors 1Neuroblastoma 1Leukemia 1Histiocytic Sarcoma 1Glioma 1Gallbladder Neoplasms 1Eyelid Squamous Cell Carcinoma 1Endometrial Neoplasms 1

Interventions

tivozanib 1atezolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Suspended × Gallbladder Neoplasms × Sarcoma × Clear all
NCT05000294 2026-02-18

Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types

University of Florida

Phase 1/2 Suspended
29 enrolled
BreastEndocrineGastrointestinalGenitourinaryGynecologicNETSarcoma

Bile Duct Neoplasms, Breast Neoplasms, Gallbladder Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Sarcoma, Vulvar Neoplasms, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡